Abstract

BackgroundThe intervention of circHIPK3 in renal carcinoma (RC) has not been reported, and thus, the current study investigated the intervention and mechanism of circHIPK3 in RC.MethodsThe expression of circHIPK3 in RC tissues and cells was detected by quantitative real-time polymerase chain reaction (qRT-PCR). Ribonuclease R (RNase R) resistance and distribution of circHIPK3 and HIPK3 were analyzed by RNase R digestion experiments and cytoplasm/nucleus separation experiments. CircHIPK3 was knocked down in ACHN and 769-P cells. Cell counting kit-8 (CCK-8), colony formation assay, scratch assay, and Transwell assay were performed to detect cell proliferation and metastasis. CircInteractome, qRT-PCR and dual-luciferase reporter assay were used to predict the target miRNAs of circHIPK3. Furthermore, a series of rescue experiments were performed to analyze the regulatory relationship between circHIPK3 and miR-485-3p. Epithelial-mesenchymal transition (EMT) and the expressions of apoptosis-associated markers were detected by Western blot and qRT-PCR. The regulatory relationship between circHIPK3 and miR-485-3p in vivo was explored by xenograft experiments, Western blot, qRT-PCR and immunohistochemistry (Ki-67).ResultsCircHIPK3 was mainly overexpressed in the cytoplasm of RC tissues and cells. Knocking down circHIPK3 inhibited the proliferation, migration, and invasion of RC cells. The expression of circHIPK3 was negatively related to that of its target gene miR-485-3p. Results of the rescue experiments showed that circHIPK3 overexpression could partially reverse the anti-carcinoma effect of miR-485-3p mimic. The specific mechanism of circHIPK3 was related to the effect of miR-485-3p on partially reversing the up-regulated expressions of Clever caspase-3, Bax, E-Cadherin and down-regulated expressions of Bcl-2, N-Cadherin and Vimentin. The results of in vivo experiments demonstrated that circHIPK3 promoted tumor growth and the expression of Ki-67 by down-regulating miR-485-3p.ConclusionCircHIPK3 promotes the proliferation and metastasis and inhibits the apoptosis of RC cells through competitively binding to miR-485-3p.

Highlights

  • The intervention of circHIPK3 in renal carcinoma (RC) has not been reported, and the current study investigated the intervention and mechanism of circHIPK3 in RC

  • CircHIPK3 was up‐regulated in RC tissues and cells, and was not sensitive to Ribonuclease R (RNase R) The expression of circHIPK3 in RC tissues and RC cells were detected, and the results showed that the expression of circHIPK3 in RC tissues was significantly higher than that in adjacent tissues (Fig. 1A, p < 0.001)

  • The results showed that there was no significant change in the expression level of circHIPK3 after RNase R treatment, while the mRNA level of Homeodomain-interacting protein kinase 3 (HIPK3) was significantly reduced after RNase R digestion (Fig. 1c, p < 0.001)

Read more

Summary

Introduction

The intervention of circHIPK3 in renal carcinoma (RC) has not been reported, and the current study investigated the intervention and mechanism of circHIPK3 in RC. Renal carcinoma (RC) originates from renal tubular epithelial cells in the renal parenchyma, and it is one of the most common malignant tumors of the urinary system. Main clinical treatments for RC are surgical resection in combination with immunotherapy, and targeted drug therapy. Molecular-targeted therapy, as a current research hotspot in refractory diseases such as carcinoma, can reduce lesions and drug damage to normal tissues with the advantages of high efficiency and low toxicity for disease prevention and treatment [4, 5]. The current moleculartargeted therapy has effectively improved the progression and prognosis of RC, the continuous use of drugs with single targets in the meantime has greatly enhanced drug resistance [6]. Researchers are currently devoted to discovering molecular-targeted drugs acting on different targets in order to reduce drug resistance and improve efficacy

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call